Addition of obinutuzumab (GA101) or rituximab to chlorambucil Improves …SYS-CON Media (press release)Is Your Business 100% Ready for the New Era of Cloud Computing and Big Data? The Only Enterprise IT Event in 2013 Covering the Entire Scope of both C…
Addition of obinutuzumab (GA101) or rituximab to chlorambucil Improves …EIN News (press release)The CLL11 trial conducted by the German CLL Study Group (GCLLSG) in collaboration with Hoffmann-La Roche for the first time compares directly the followin…
|
COMUNICADO: La adición de obinutuzumab o rituximab a clorambucil mejora …
Lainformacion.com ESTOCOLMO, June 14, 2013 /PRNewswire/ — — La adición de obinutuzumab (GA101) o rituximab a chlorambucil mejora los resultados para pacientes mayores con leucemia linfocítica crónica (CLL) y condiciones médicas coexistentes (comorbilidades) El … |
|
COMUNICADO: La adición de obinutuzumab o rituximab a clorambucil mejora …
Europa Press El ensayo CLL11 realizado por German CLL Study Group (GCLLSG) en colaboración con Hoffmann-La Roche por primera vez compara directamente los siguientes tratamientos en personas mayores con comorbilidades: GA101 más clorambucil, rituximab … |
BioNews Texas |
MD Anderson Researcher Reports Idelalisib and Rituximab Produce Responses …
BioNews Texas Idelalisib Dr. Susan M. O’Brien from the University of Texas MD Anderson Cancer Center in Houston reported that pairing rituximab with the experimental agent idelalisib can improve the management of small lymphocytic lymphoma or treatment- naive … |
Cytarabine Improves Combination Therapy for Mantle Cell LymphomaClinical Oncology NewsFrom the Journal of Clinical Oncology. The addition of cytarabine to bendamustine plus rituximab (R-BAC) as combination therapy for older patients with mantle cell ly…
PDL BioPharma CEO Presents at Goldman Sachs Healthcare Conference …Seeking AlphaIn looking for second generation products rituxan they basically divided the franchisee in half, half were targeted towards blood-borne cancers of rituximab being in that…
|
Idelalisib and rituximab produce responses in 97% with CLL
The Oncology Report CHICAGO – When paired with rituximab, the experimental agent idelalisib was associated with durable progression-free survival rates in older patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma, Dr. Susan M. O’Brien … |
Bendamustine plus rituximab shows promise in relapsed, refractory DLBCLHealioThe combination of bendamustine and rituximab was effective and well tolerated as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma who und…
Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in …Benzinga1 Moreover, given that the anti-CD20 veltuzumab also compared well to published results with rituximab,^2,3 the Company is conducting a Phase I/II study to evaluate the …